Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS

References

• ZingmondDSKilbourneAMJusticeACDifferences in symptom expression in older HIV-positive patients: the Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experienceJ Acquir Immune Defic Syndr200333Suppl 2S84S9212853857
   PubMed Web of Science ®Google Scholar
• MacArthurRDDuPontHLEtiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy eraClin Infect Dis201255686086722700829
   PubMed Web of Science ®Google Scholar
• LorenzKAShapiroMFAschSMBozzetteSAHaysRDAssociations of symptoms and health-related quality of life: findings from a national study of persons with HIV infectionAnn Intern Med20011349 Pt 285486011346321
   PubMed Web of Science ®Google Scholar
• SiddiquiUBiniEJChandaranaKPrevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapyJ Clin Gastroenterol200741548449017450031
   PubMed Web of Science ®Google Scholar
• HillABalkinARisk factors for gastrointestinal adverse events in HIV treated and untreated patientsAIDS Rev2009111303819290032
   PubMed Web of Science ®Google Scholar
• SiegelKSchrimshawEWBrown-BradleyCJLekasHMSources of emotional distress associated with diarrhea among late middle-age and older HIV-infected adultsJ Pain Symptom Manage201040335336920579836
   PubMed Web of Science ®Google Scholar
• TradtrantipLNamkungWVerkmanASCrofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channelsMol Pharmacol2010771697819808995
   PubMed Web of Science ®Google Scholar
• ZhangWFujiiNNarenAPRecent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheasFuture Med Chem20124332934522393940
   PubMed Web of Science ®Google Scholar
• ThiagarajahJRVerkmanASCFTR inhibitors for treating diarrheal diseaseClin Pharmacol Ther201292328729022850599
   PubMed Web of Science ®Google Scholar
• BarrettKEKeelySJChloride secretion by the intestinal epithelium: molecular basis and regulatory aspectsAnnu Rev Physiol20006253557210845102
   PubMed Web of Science ®Google Scholar
• ShermanDSFishDNManagement of protease inhibitor-associated diarrheaClin Infect Dis200030690891410854364
   PubMed Web of Science ®Google Scholar
• Berni CananiRSecondoAPassarielloAZinc inhibits calcium-mediated and nitric oxide-mediated ion secretion in human enterocytesEur J Pharmacol20106262–326627019819236
   PubMed Web of Science ®Google Scholar
• PrimiMPBuenoLBaumerPBerardHLecomteJMRacecadotril demonstrates intestinal antisecretory activity in vivoAliment Pharmacol Ther199913Suppl 63710646045
   PubMed Web of Science ®Google Scholar
• HolodniyMKochJMistalMA double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDSAm J Gastroenterol199994113267327310566728
   PubMed Web of Science ®Google Scholar
• DiCesareDDuPontHLMathewsonJJA double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and MexicoAm J Gastroenterol200297102585258812385443
   PubMed Web of Science ®Google Scholar
• MangelAWChaturvediPEvaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patientsDigestion200878418018619092244
   PubMed Web of Science ®Google Scholar
• BardhanPSharmaABolmallCSafety and efficacy of a novel anti-secretory anti-diarrheal agent crofelemer (NP-303), in the treatment of adult acute infectious diarrhea and cholera, with or without the use of antibioticsProceedings of the US–Japan CMSP: 13th International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim – Focused on Enteric DiseasesApril 6–9, 2009Kolkata, India
   Google Scholar
• KartalijaMSandeMADiarrhea and AIDS in the era of highly active antiretroviral therapyClin Infect Dis1999284701705 quiz 706–70710825021
   PubMed Web of Science ®Google Scholar
• BrenchleyJMDouekDCHIV infection and the gastrointestinal immune systemMucosal Immunol200811233019079157
   PubMed Web of Science ®Google Scholar
• MalanNSuJManciniMCASTLE Study TeamGastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE studyAIDS Care201022667768620467943
   PubMed Web of Science ®Google Scholar
• JohnsonMGrinsztejnBRodriguezCAtazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresAIDS200519768569415821394
   PubMed Web of Science ®Google Scholar
• JohnsonMGrinsztejnBRodriguezC96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failuresAIDS200620571171816514301
   PubMed Web of Science ®Google Scholar
• MolinaJMAndrade-VillanuevaJEchevarriaJCASTLE Study TeamOnce-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyLancet2008372963964665518722869
   PubMed Web of Science ®Google Scholar
• MolinaJMAndrade-VillanuevaJEchevarriaJCASTLE Study TeamOnce-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE studyJ Acquir Immune Defic Syndr201053332333220032785
   PubMed Web of Science ®Google Scholar
• BánhegyiDKatlamaCda CunhaCAWeek 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITANCurr HIV Res201210217118122339125
   PubMed Web of Science ®Google Scholar
• MadrugaJVBergerDMcMurchieMTITAN Study GroupEfficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trialLancet20073709581495817617272
   PubMed Web of Science ®Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS200923131679168819487905
   PubMed Web of Science ®Google Scholar
• OrtizRDejesusEKhanlouHEfficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48AIDS200822121389139718614861
   PubMed Web of Science ®Google Scholar
• WalmsleySAvihingsanonASlimJGemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adultsJ Acquir Immune Defic Syndr200950436737419214123
   PubMed Web of Science ®Google Scholar
• EronJJrYeniPGatheJJrKLEAN Study TeamThe KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialLancet2006368953447648216890834
   PubMed Web of Science ®Google Scholar
• PulidoFEstradaVBarilJGLong-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeksHIV Clin Trials2009102768719487177
   PubMed Web of Science ®Google Scholar
• HicksCBDeJesusESloanLMCOL100758 Study TeamComparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758AIDS Res Hum Retroviruses200925439540319320570
   PubMed Web of Science ®Google Scholar
• Braga NetoMBAguiarCVMacielJGEvaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in miceBMC Gastroenterol2010109020701796
   PubMed Web of Science ®Google Scholar
• RufoPALinPWAndradeADiarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl-secretion by T84 cells via prolongation of cytosolic Ca2+ signalingAm J Physiol Cell Physiol20042865C998C100815075198
   PubMed Web of Science ®Google Scholar
• MacArthurRHawkinsTBrownSLaMarcaAChaturvediPErnstJADVENT Trial: crofelemer for the treatment of secretory diarrhea in HIV+ individualsProceedings of the 19th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2012Seattle, WA
   Google Scholar
• Fulyzaq® (crofelemer) [prescribing Information]Raleigh, NCSalix Pharmaceuticals, Inc2013 Available from: http://www.fulyzaq.com/Accessed April 1, 2013
   Google Scholar
• FischerHMachenTEWiddicombeJHA novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cellsJ Ethnopharmacol2004932–335135715234776
   PubMed Web of Science ®Google Scholar
• UbillasRJoladSBrueningRCSP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri (Sangre de Drago)Phytomedicine1994127710623195881
   PubMedGoogle Scholar
• GabrielSEDavenportSESteagallRJVimalVCarlsonTRozhonEJA novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretionAm J Physiol19992761 Pt 1G58G639886979
   PubMed Web of Science ®Google Scholar
• MacArthurRHawkinsTBrownSSafety and tolerability of crofelemer 125 mg for treating non-infectious diarrhea in HIV⁺ individuals: results from double-blind and open-label studiesProceedings of the 20th Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2013Atlanta, GA
   Google Scholar